

## Disclosures

### Personal Commercial (15)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AbbVie, Inc.	Research/Research Grants ‡ <i>Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study</i>	Significant (>= \$5,000)	<i>General Cardiology</i>
Alnylam	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Other</i>
Ardelyx	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Other</i>
Astra Zeneca	Research/Research Grants ‡ <i>STRENGTH - Epanova in High Risk Patients with Hypertriglyceridemia</i>	Significant (>= \$5,000)	<i>General Cardiology Prevention</i>
Brainstorm Cell	Consultant Fees/Honoraria	None (\$0)	<i>Other</i>
CSL Behring	Research/Research Grants	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions General Cardiology</i>
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Esperion	Research/Research Grants ‡ <i>CLEAR Outcomes - Effects of Bempedoic Acid (ETC 1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardiovascular Disease who are Statin Intolerant</i>	Significant (>= \$5,000)	<i>Prevention</i>
Glaxo Smithkline	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
i20	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Other</i>
Medscape	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Medtronic	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Novartis	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Novo Nordisk	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
ReCor	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ *Commercial Funding Source* | ‡ *Trial Name*

## Agreement

**Certified Education Attestation** | Signed on 9/20/2023

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 9/20/2023

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 9/20/2023

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 9/20/2023

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.